Clinical trials: Obesity Overweight
Overweight and Obese Adults, Obese Patients (BMI ≥ 30 kg/m²)
Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
Obesity is a growing public health problem in Sweden, but access to care varies depending on geographical location. Eatit´s multimodal digitally dietitian-supported lifestyle intervention offers an accessible treatment…
- Trial name
- NCT07183228
- Testing
- Lifestyle Intervention for Obesity
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Eatit AB
Healthy Participants
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
- Trial name
- NCT07534592
- Testing
- Elecoglipron, Atorvastatin, Rosuvastatin
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight.
- Trial name
- NCT07808060
- Testing
- Eloralintide, Combined oral contraceptive
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Abdominal Obesity
Eon™ FR 1064 Full Abdomen Clinical Study Protocol
This is a marketing study intended to provide additional data for marketing purposes for the eon™ FR is FDA 510(k) which has been cleared for non-invasive lipolysis of the abdomen to achieve disruption of adipocyte cells intended…
- Trial name
- NCT04842110
- Testing
- Experimental: eonTM FR 1064 nm device
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dominion Aesthetic Technologies, Inc.
Obesity, Overweight and Obesity
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased…
- Trial name
- NCT06606483
- Testing
- MDR-001
- Where
- 19 sites in China
- Volunteers
- 300 people
- Sponsor
- MindRank AI Ltd
Postprandial Glycemic Control, Prediabetic Overweight and Obese Adults
A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
The goal of part 1 of this clinical trial is to investigate the tolerability of Lembas Edge in healthy adults. The objective of Part 2 of this study is to investigate the efficacy of Lembas Edge on postprandial glycemic control…
- Trial name
- NCT07711288
- Testing
- Low dose alpha-galactosidase-derived peptide, Medium dose alpha-galactosidase-derived peptide, High dose alpha-galactosidase-derived peptide
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lembas
Obesity, Healthy Volunteers
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and…
- Trial name
- NCT06106334
- Testing
- S309309, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers
The purpose of this study is to evaluate the safety and tolerance of single intravenous (through a vein) doses of trodusquemine. Different amounts of trodusquemine will be given to each volunteer group throughout the study.
- Trial name
- NCT00509132
- Testing
- trodusquemine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Genaera Corporation
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Obese, Obesity
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI…
- Conditions
- Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
- Trial name
- GSBR-1290 (NCT07400588)
- Testing
- Aleniglipron
- Where
- 16 sites in United States
- Volunteers
- 58 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06567327
- Testing
- Danuglipron, Atorvastatin, Rosuvastatin
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Obesity, Type 2 Diabetes
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
- Trial name
- NCT00553787
- Testing
- VI-0521
- Where
- 6 sites in United States
- Volunteers
- 2,487 people
- Sponsor
- VIVUS LLC
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07684144
- Testing
- Maridebart Cafraglutide
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 950 people
- Sponsor
- Amgen
Healthy Participants
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
- Trial name
- NCT05511025
- Testing
- AZD6234, Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obesity
Study Exploring the Supportive Effect of Acarbose in Weight Management
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination…
- Trial name
- NCT05934110
- Testing
- EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,
- Where
- 3 sites in Sweden
- Volunteers
- 320 people
- Sponsor
- Empros Pharma AB
Obesity
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause.
- Trial name
- NCT07850050
- Testing
- Survodutide
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Obesity, Morbid
Swedish Adjustable Gastric Banding Observational Cohort Study
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France.
- Trial name
- NCT01183975
- Where
- France
- Volunteers
- 517 people
- Sponsor
- Ethicon Endo-Surgery (Europe) GmbH
Overweight and Obesity
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity
The effect of Epitomee Capsule on body weight in patients with overweight and obesity with and without Prediabetes
- Trial name
- RESET (NCT04222322)
- Testing
- Epitomee Capsule
- Where
- 9 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Obesity or Overweight, Type 2 Diabetes
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.
- Trial name
- NCT06988553
- Testing
- AZD5004
- Where
- 6 sites in China
- Volunteers
- 45 people
- Sponsor
- Eccogene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.